Literature DB >> 20425623

Active surveillance for prostate cancer: a review.

Laurence Klotz1.   

Abstract

Active surveillance is a solution to the widely acknowledged problem of overdiagnosis and overtreatment of clinically insignificant disease which accompanies early detection of prostate cancer using prostate-specific antigen (PSA) and biopsy. It is an approach to the management of favorable-risk prostate cancer which uses the opportunity provided by the long natural history of the disease to incorporate a period of initial observation into patient management. The basic concept is that most men diagnosed with low-grade, small-volume disease are not destined to have any clinical manifestations of the condition during their lifetime. However, a subset of patients with favorable-risk prostate cancer is at risk, due to either the presence of higher-risk disease not apparent at diagnosis or progression to a more aggressive phenotype over time. These patients can be identified with reasonable accuracy by close follow-up, including serial PSAs and biopsies, and treated effectively in most cases. The rationale, patient selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425623     DOI: 10.1007/s11934-010-0110-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  33 in total

1.  Prostate biopsy: how many cores are enough?

Authors:  Joseph C Presti
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

2.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Authors:  Richard Choo; Laurence Klotz; Cyril Danjoux; Gerard C Morton; Gerrit DeBoer; Ewa Szumacher; Neil Fleshner; Peter Bunting; George Hruby
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Authors:  Monique J Roobol; Melissa Kerkhof; Fritz H Schröder; Jack Cuzick; Peter Sasieni; Matti Hakama; Ulf Hakan Stenman; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis Denis; Franz Recker; Antonio Berenguer; Mirja Ruutu; Paula Kujala; Chris H Bangma; Gunnar Aus; Teuvo L J Tammela; Arnauld Villers; Xavier Rebillard; Sue M Moss; Harry J de Koning; Jonas Hugosson; Anssi Auvinen
Journal:  Eur Urol       Date:  2009-07-28       Impact factor: 20.096

5.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

Authors:  Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

7.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Under diagnosis and over diagnosis of prostate cancer.

Authors:  Theresa Graif; Stacy Loeb; Kimberly A Roehl; Sara N Gashti; Christopher Griffin; Xiaoying Yu; William J Catalona
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

Review 9.  Active surveillance with selective radical treatment for localized prostate cancer.

Authors:  Nicholas J van As; Chris C Parker
Journal:  Cancer J       Date:  2007 Sep-Oct       Impact factor: 3.360

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

View more
  22 in total

1.  Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance.

Authors:  Tae Heon Kim; Jae Yong Jeong; Sin Woo Lee; Chan Kyo Kim; Byung Kwan Park; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han Yong Choi; Seong Soo Jeon
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

Review 2.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

Review 3.  Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up.

Authors:  Berrend G Muller; Willemien van den Bos; Peter A Pinto; Jean J de la Rosette
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

4.  Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer.

Authors:  Ann S Hamilton; Xiao-Cheng Wu; Joseph Lipscomb; Steven T Fleming; Mary Lo; Dian Wang; Michael Goodman; Alex Ho; Jean B Owen; Chandrika Rao; Robert R German
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

5.  Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.

Authors:  Jenny L Donovan
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 6.  Active surveillance for prostate cancer: past, present and future.

Authors:  Eric A Singer; Aradhana Kaushal; Baris Turkbey; Anna Couvillon; Peter A Pinto; Howard L Parnes
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

Review 7.  PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.

Authors:  Kirsten Bouchelouche; Scott T Tagawa; Stanley J Goldsmith; Baris Turkbey; Jacek Capala; Peter Choyke
Journal:  Semin Nucl Med       Date:  2011-01       Impact factor: 4.446

8.  Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.

Authors:  Amy N Luckenbaugh; Gregory B Auffenberg; Scott R Hawken; Apoorv Dhir; Susan Linsell; Sanjeev Kaul; David C Miller
Journal:  J Urol       Date:  2016-09-20       Impact factor: 7.450

9.  Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Authors:  Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

10.  A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype.

Authors:  Guangjing Zhu; Zhi Liu; Jonathan I Epstein; Christine Davis; Christhunesa S Christudass; H Ballentine Carter; Patricia Landis; Hui Zhang; Joon-Yong Chung; Stephen M Hewitt; M Craig Miller; Robert W Veltri
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-24       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.